Press Release
Galectin Therapeutics Board Member John Mauldin Plans to Purchase Stock Under 10b5-1 Plan; Company Featured in his e-newsletter "Thoughts from the Frontline"
NEWTON, Mass., Oct 03, 2011 (BUSINESS WIRE) -- Galectin TherapeuticsInc. (OTC: GALT) today announced that John Mauldin, a member of its Board of Directors, plans to purchase Company stock on a periodic basis by entering into a 10b5-1 plan, and on October 1st, featured the Company in his e-newsletter, "Thoughts from the Frontline", a highly acclaimed newsletter that is primarily focused on private money management, financial services, and investments. Each week, more than one million readers turn to Mauldin for his penetrating view on Wall Street, global markets, and economic history. Mauldin's article can be read at http://howestreet.com/2011/10/tough-choices-big-opportunities. SEC Rule 10b5-1 allows officers, directors and other insiders of publicly traded companies to transact in their company shares at all times, not just during open trading windows.
John Mauldin is a renowned financial expert and New York Times best-selling author. Mr. Mauldin is currently the President of Millennium Wave Advisors. Prior to that position, he was Chief Executive Officer of the American Bureau of Economic Research. Mr. Mauldin is a regular contributor to publications including The Financial Times and The Daily Reckoning, as well as a frequent guest on CNBC, Yahoo Tech Ticker, and Bloomberg TV. He is author of Thoughts from the Frontline, a free weekly e-newsletter, and several books, including: Bull's Eye Investing: Targeting Real Returns in a Smoke and Mirrors Market, Just One Thing: Twelve of the World's Best Investors Reveal the One Strategy You Can't Overlook, and Endgame: The End of the Debt Supercycle and How it Changes Everything. He also edits Outside the Box, a free weekly e-letter. Mr. Mauldin holds a B.A. from Rice University and a Master of Divinity degree from Southwestern Baptist Theological Seminary.
About Galectin Therapeutics
Galectin Therapeutics (OTC: GALT) is developing promising carbohydrate-based therapies for fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at http://www.galectintherapeutics.com
Forward Looking Statements
This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.
SOURCE: Galectin Therapeutics Inc.
Galectin Therapeutics Inc.
Anthony D. Squeglia, 617.559.0033
Chief Financial Officer